Research Article

The Prevalence and Associated Factors of Hypertension among HIV Patients

Table 1

Sociodemographic and clinical characteristics of the study sample.

VariablesMale n = 293
Mean (SD) or % (n)
Female n = 646
Mean (SD) or % (n)
Total n = 939
Mean (SD) or % (n)

Age in years47 (11.5)43 (10.2)44 (10.7)
SBP (mmHg)127.9 (17.9)121.3 (17.8)123.4 (18.1)
DBP (mmHg)75.5 (11.7)73.4 (10.1)74.1 (10.7)
Weight (kg)66.5 (13.1)65.4 (13.5)65.7 (13.4)
Height (meters)1.70 (0.1)1.59 (0.1)1.62 (0.1)
BMI (kg/m2)23.1 (4.2)25.8 (5.1)24.9 (4.9)

BMI categories
Underweight (BMI ≤18.4)9.9 (29)56.7 (38)7.1 (67)
Normal (BMI 18.5–24.9)61.8 (181)40.4 (261)47.1 (442)
Overweight/obese (BMI≥25)28.3 (83)53.7 (347)45.8 (430)

Blood pressure categories
Normal BP (SBP < 130 and DBP < 85 mmHg)59.7 (175)70.6 (456)67.2 (631)
Prehypertensive (SBP of 130–139 and/or DBP 85–89 mmHg)15.0 (44)13.5 (87)131 (13.9)
Hypertensive (SBP ≥140 and/or DBP ≥ 90 mmHg)25.3 (74)15.9 (103)18.9 (177)

ARV drugs
TDF/3TC/EFV12 (35)40.6 (262)31.6 (297)
D4T/3TC/NVP15.4 (45)16.7 (108)16.3 (153)
TDF/3TC/NVP1.7 (5)7.6 (49)5.8 (54)
TDF/3TC/DTG50.5 (148)14.9 (96)26 (244)
TDF or AZT/3TC/LPV/r or ATV/r4.8 (14)3.9 (25)4.2 (39)
AZT/3TC/NVP3.1 (9)7.7 (50)6.3 (59)
3TC/D4T/EFV8.9 (26)5.4 (35)6.5 (61)
Others3.8 (11)3.2 (21)3.4 (32)

ART regimen
NNRTIs and NRTIs38.6 (113)77.6 (501)65.4 (614)
NRTIs and PIs5.8 (17)4.6 (30)5.0 (47)
NRTIs and INSTIs55.6 (163)17.8 (115)29.6 (278)

Duration of ARV therapy
<2 years13.3 (39)10.8 (70)11.6 (109)
≥2 years86.7 (254)89.2 (576)88.4 (830)

History of smoking
Yes14.3 (42)1.9 (12)5.8(54)
No85.7 (251)98.1 (634)94.2(885)

History of alcohol consumption
Yes22.1 (59)6.1 (39)11.1 (95)
No77.9 (208)93.9 (550)88.9 (758)

SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; ARV: antiretroviral; ART: antiretroviral therapy; AZT: zidovudine; 3TC: lamivudine; NVP: nevirapine; EFV: efavirenz; TDF: tenofovir disoproxil fumarate; DTG: dolutegravir; D4T: stavudine; LPV/r: lopinavir/ritonavir; ATV/r: atazanavir/ritonavir; NNRTIs: nonnucleoside reverse transcriptase inhibitors; NRTI: nucleoside and nucleotide reverse transcriptase inhibitors; INSTIs: integrase strand transfer inhibitor.